Our deep pipeline and cash runway into 2030 enable IDEAYA to advance key combinations and to address multiple indications ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
Many AI tools are free and easy to use. They can save time, improve productivity, and help entrepreneurs grow their business.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback